Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Alexander P. J. Vlaar*, Sanne de Bruin, Matthias Busch, Sjoerd A. M. E. G. Timmermans, Ingeborg E. van Zeggeren, Rutger Koning, Liora ter Horst, Esther B. Bulle, Frank E. H. P. van Baarle, Marcel C. G. van de Poll, E. Marleen Kemper, Iwan C. C. van der Horst, Marcus J. Schultz, Janneke Horn, Frederique Paulus, Lieuwe D. Bos, W. Joost Wiersinga, Martin Witzenrath, Simon Rueckinger, Korinna PilzMatthijs C. Brouwer, Ren-Feng Guo, Leo Heunks, Pieter van Paassen, Niels C. Riedemann, Diederik van de Beek

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)E764-E773
Number of pages10
JournalThe Lancet Rheumatology
Volume2
Issue number12
DOIs
Publication statusPublished - Dec 2020

Keywords

  • TISSUE FACTOR
  • COMPLEMENT ACTIVATION
  • C5A
  • NEUTROPHILS

Cite this